2018
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression
Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications 2018, 9: 4832. PMID: 30510245, PMCID: PMC6277390, DOI: 10.1038/s41467-018-07305-8.Peer-Reviewed Original ResearchConceptsIL-17Multiple myelomaTh17 cellsDisease progressionBone marrowInterleukin-17-producing cellsFaster disease progressionMultiple myeloma progressionExtramucosal tumorsMM patientsAvailable therapiesIL-17RAIL-5Myeloma progressionPlasma cellsGut microbiotaCommensal bacteriaInnate immunityIntestinal microbesMurine plasma cellsPrevotella heparinolyticaEosinophilsMiceProgressionSTAT3 phosphorylation
2005
Variation in microbiologic profiles among pregnant women with bacterial vaginosis
Pereira L, Culhane J, McCollum K, Agnew K, Nyirjesy P. Variation in microbiologic profiles among pregnant women with bacterial vaginosis. American Journal Of Obstetrics And Gynecology 2005, 193: 746-751. PMID: 16150269, DOI: 10.1016/j.ajog.2005.01.069.Peer-Reviewed Original ResearchConceptsPregnant womenNon-Hispanic blacksLifetime sexual partnersClue cellsUnadjusted analysesBacterial vaginosisMicrobiologic profileMobiluncus sppWet mountSexual partnersPositive pregnant womenMore lifetime sexual partnersAbnormal vaginal dischargeAmine odorMultiple logistic regressionChi-square testClinical characteristicsAdjusted analysisClinical outcomesClinical findingsPhysician diagnosisVaginal dischargeNugent criteriaClinical signsM group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply